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ABSTRACT 
The Panel on Food Additives and Nutrient Sources added to Food provides a scientific opinion re-evaluating the 
safety of Patent Blue V (E 131). Patent Blue V (E 131) is a triarylmethane dye permitted for use as a food 
additive in the EU, that has been previously evaluated by JECFA in 1970 and 1975 and the EU SCF in 1983; 
JECFA established a Temporary Acceptable Daily Intake (ADI) of 0-1 mg/kg bw/day in 1970, but withdrew it in 
1975. Until now JECFA has not allocated an ADI to Patent Blue V (E 131). The SCF established an ADI of 0-15 
mg/kg bw/day. The Panel was not provided with a newly submitted dossier and based its evaluation on previous 
evaluations, additional literature that became available since then and the data available following a public call 
for data. The Panel concluded that the present dataset provides a rationale for a re-definition of the ADI. Using 
the NOAEL of 500 mg/kg bw/day derived from a chronic toxicity study in mice and applying an uncertainty 
factor of 100 to this NOAEL, the Panel establishes an ADI of 5 mg/kg bw/day. The Panel noted that at the 
maximum permitted levels of use of Patent Blue V (E 131), exposure estimates for high consumers are above the 
ADI of 5 mg/kg bw/day in toddlers and children. At the maximum reported use levels of Patent Blue V (E 131), 
exposure estimates are below the ADI of 5 mg/kg bw/day for all groups of the population. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission to the European Food Safety Authority (EFSA), 
the Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to deliver a 
scientific opinion re-evaluating the safety of Patent Blue V (E 131) when used as a food colouring 
substance.  
Patent Blue V (E 131) is a triarylmethane dye authorised as a food additive in the EU, that has been 
previously evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1970 
and 1975 and the EU Scientific Committee for Food (SCF) in 1983; JECFA established a Temporary 
Acceptable Daily Intake (ADI) of 0-1 mg/kg bw/day in 1970, but withdrew it in 1975. Until now 
JECFA has not allocated an ADI to Patent Blue V (E 131), whereas the SCF established an ADI of 0-
15 mg/kg bw/day. 
Data available on the absorption, distribution, metabolism and excretion of Patent Blue V after oral 
administration in rats and dogs show that  Patent Blue V  has low absorption, limited systemic 
availability and is mainly excreted unchanged in the faeces. In vitro data on the metabolism in humans 
and in rats showed that Patent Blue V is not metabolised. 
Patent Blue V, in old studies, did not demonstrate any evidence of mutagenic activity in strains of 
tryptophan-requiring Escherichia coli and histidine-requiring Salmonella typhimurium (four strains), 
both with, and without metabolic activation. In contrast, in an Ames test performed in 2010 according 
to OECD Guidelines, high concentrations of Patent Blue V induced biologically significant increases 
in the number of revertants in the TA98 strain in the presence of metabolic activation. In the presence 
of low concentrations, there were no effects. This observation could suggest that an impurity present 
in the food colour could be responsible for this mutagenic effect.  
A mouse lymphoma assay performed in 2011 according to OECD Guidelines with Patent Blue V in 
accordance with EU specifications, was negative. 
Two in vivo micronucleus assays are available for Patent Blue V. The first one (in 1986), performed in 
mouse after intraperitonal injection, was evaluated as not reliable. In contrast, the second one (in 
2011), performed in rat after i.v. injection according to OECD guidelines did not show any clastogenic 
effect. 
In an unpublished  study report, the DNA damaging capabilities of Patent Blue V (E 131) were 
assessed in the in vivo single cell gel/Comet assay in rats. The Panel concluded that Patent Blue V (E 
131) did not induce any effect in DNA migration in rat liver, jejunum/ileum and peripheral blood after 
in vivo treatment under the reported experimental conditions. According to new studies provided by 
industry on request of EFSA, the Panel considered that Patent Blue V (E 131) (at purity level > than 
90 %) was not of concern with respect to genotoxicity. 
There is one chronic toxicity study performed in mice. In the absence of the full study report, the Panel 
considered that the haematological effects observed at the highest dose tested were biologically 
significant. Therefore, the Panel considered that a NOAEL of 500 mg/kg bw/day (intermediate dose 
tested) can be derived from this study, based on growth reduction and alterations of haematological 
parameters reported at the highest dose tested mainly in males. Based on the data of this study, the 
Panel considers that Patent Blue V has no carcinogenic effects. 
A reproductive toxicity study in mice did not reveal adverse effects. The NOAEL from this study is 
the highest dose tested, 1500 mg/kg bw/day.  
No effects have been identified in a developmental study in rats. The NOAEL derived by the Panel is 
500 mg/kg bw/day, the highest dose tested. Re-evaluation of Patent Blue V (E 131) as a food additive 
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The Panel concluded that the present dataset provided a rationale for a re-definition of the ADI. Using 
the NOAEL of 500 mg/kg bw/day from a chronic toxicity study in mice and applying an uncertainty 
factor of 100 to this NOAEL, the Panel established an ADI of 5 mg/kg bw/day for Patent Blue V of 
purity at least 90 %.  
Exposure to Patent Blue V from its use as a food additive has been calculated by using the Maximum 
Permitted Levels (MPLs) as indicated in the Commission Regulation No 1129/2011 and by using data 
on reported use levels provided by the food industry or data reported on analytical levels provided by 
national authorities or found in the literature. These data were combined with national consumption 
data for the population groups of toddlers, children, adolescents, adults and the elderly from the EFSA 
Comprehensive Food Consumption Database. 
When considering MPLs, estimates calculated for toddlers, children, adolescents, adults and the 
elderly give dietary exposures at the mean in the range of 1-4.5, 1.1-3.6, 0.5-1.8, 0.3-1.4, and 0.2-0.6 
mg/kg bw/day, respectively. High level exposures for these population groups were calculated to be in 
the range of 2.9-7.5, 2.4-7, 1.3-3.7, 0.9-2.9 and 0.6-1.5  mg/kg bw/day, respectively. The main 
contributors to the total anticipated exposure to Patent Blue V (>10 %) for adults were flavoured 
drinks (with sugar or sweeteners) (11-48  %), flavoured fermented milk products (14-29  %), fine 
bakery wares (11-34  %), and sauces (12-29  %). For children, main contributors were flavoured 
fermented milk products (13-32 %), fine bakery wares (11-45 %), and sauces (11-23 %).  
When considering maximum reported use levels or maximum analytical levels, estimates calculated 
for toddlers, children, adolescents, adults and the elderly give dietary exposures at the mean in the 
range of 0.2-1.5, 0.4-1.2, 0.3-0.7, 0.1-0.5 and 0.04-0.3  mg/kg bw/day, respectively. High level 
exposures for these population groups were calculated to be in the range of 0.6-2.7, 1-2.4, 0.7-1.7, 0.4-
1 and 0.1-0.8 mg/kg bw/day, respectively. The main contributors to the total anticipated exposure to 
Patent Blue V (>10 %) for adults were flavoured drinks with sweeteners (12-38 %), and fine bakery 
wares (15-64 %). For children, main contributors were fine bakery wares (10-70 %), and flavoured 
drinks with sugar (10-31 %).  
The Panel noted that at the maximum permitted levels of use of Patent Blue V, exposure estimates for 
high consumers are above the ADI of 5 mg/kg bw/day in toddlers and children. At the maximum 
reported use levels of Patent Blue V, exposure estimates are below the ADI of 5 mg/kg bw/day for all 
groups of the population. 
The Panel further noted that the specifications for Patent Blue V need to be updated with respect to the 
percentage of material not accounted for that may represent sodium chloride and/or sodium sulphate as 
the principal uncoloured components. 
The Panel noted that the JECFA specification for chromium is < 50 mg/kg, whereas no specification 
for chromium is required in EC specifications. 
The Panel noted that the aluminium lake of the colour could add to the daily intake of aluminium for 
which a Tolerable Weekly Intake (TWI) of 1 mg aluminium/kg bw/week has been established, and 
that therefore specifications for the maximum level of aluminium in the lakes may be required. Re-evaluation of Patent Blue V (E 131) as a food additive 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives 
requires that food additives are subject to a safety evaluation by the European Food Safety Authority 
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food 
additives must be kept under continuous observation and must be re-evaluated by EFSA.  
For this purpose, a programme for the re-evaluation of food additives that were already permitted in 
the European Union before 20 January 2009 has been set up under the Regulation (EU) No 257/2010
4
The order of priorities for the re-evaluation of the currently approved food additives should be set on 
the basis of the following criteria: the time since the last evaluation of a food additive by the Scientific 
Committee on Food (SCF) or by EFSA, the availability of new scientific evidence, the extent of use of 
a food additive in food and the human exposure to the food additive taking also into account the 
outcome of the Report from the Commission on Dietary Food Additive Intake in the EU
. 
This Regulation also foresees that food additives are re-evaluated whenever necessary in light of 
changing conditions of use and new scientific information. For efficiency and practical purposes, the 
re-evaluation should, as far as possible, be conducted by group of food additives according to the main 
functional class to which they belong.  
5 of 2001. The 
report “Food additives in Europe 2000
6
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised 
food additives. However, as a result of adoption of Regulation (EU) 257/2010 the 2003 Terms of 
References are replaced by those below.  
” submitted by the Nordic Council of Ministers to the 
Commission, provides additional information for the prioritisation of additives for re-evaluation. As 
colours were among the first additives to be evaluated, these food additives should be re-evaluated 
with a highest priority.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Commission asks the European Food Safety Authority to re-evaluate the safety of food additives 
already permitted in the Union before 2009 and to issue scientific opinions on these additives, taking 
especially into account the priorities, procedures and deadlines that are enshrined in the Regulation 
(EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved food 
additives in accordance with the Regulation (EC) No 1333/2008 of the European Parliament and of the 
Council on food additives.  
                                                 
4 Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved 
food additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food 
additives. OJ L 80, 26.03.2010, p.19. 
5 Report from the Commission on dietary food additive intake in the European Union. COM(2001) 542 final. 
6 Food Additives in Europe 2000, Status of safety assessments of food additives presently permitted in the EU, Nordic 
Council of Ministers, TemaNord 2002:560. Re-evaluation of Patent Blue V (E 131) as a food additive 
 
EFSA Journal 2013;11(3):2818  6 
 
ASSESSMENT 
1.  Introduction 
The present opinion deals with the re-evaluation of the safety of Patent Blue V (E 131) when used as a 
food colouring substance. 
Patent Blue V (E 131) is authorised as a food additive in the EU and has been previously evaluated by 
the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1970 and 1975, and the EU 
Scientific Committee for Food (SCF) in 1983. 
The Panel on Food Additives and Nutrient Sources added to Food (ANS) was not provided with a 
newly submitted dossier and based its evaluation on previous evaluations, additional literature that 
became available since then and the data available following a public call for data
7,8,9
2.  Technical data 
. The Panel noted 
that not all original studies on which previous evaluations were based were available for re-evaluation 
by the Panel. 
2.1.  Identity of the substance 
Patent Blue V (E 131) is a triarylmethane food colour that exists under two inner salt (calcium and 
sodium) forms. 
The systematic name for the calcium salt is N-(4-((4-(diethylamino)phenyl)(5-hydroxy-2,4-
disulfophenyl)methyl-ene)-2,5-cyclohexadien-1-ylidene)-N-ethylethanaminium, hydroxide, inner salt, 
calcium salt (2:1). The molecular formula is C27H32N2O7S2.1/2Ca, the molecular weight is 579.72 
g/mol, the CAS Registry Number is 3536-49-0, the EINECS number is 222-573-8 and the Colour 
Index number is 42051 (ChemIDplus, 2012). 
The systematic name for the sodium salt is N-(4-((4-(diethylamino)phenyl)(2,4-
disulfophenyl)methylene)-2,5-cyclohexadien-1-ylidene)-N-ethylethanaminium, hydroxide, inner salt, 
sodium salt. The molecular formula is C27H32N2O7S2
.Na, the molecular weight is 582.67 g/mol, the 
CAS Registry Number is 129-17-9, the EINECS number is 204-934-1 and the Colour Index number is 
42045 (ChemIDplus, 2012).  
The structural formula for the two salt forms is depicted in Figure 1: 
                                                 
7 Call for scientific data on food colours to support re-evaluation of all food colours authorised under the EU legislation. 
Published on 8 December 2006. Available at: http://www.efsa.europa.eu/en/dataclosed/call/afc061208.htm 
8  Call for scientific data on Patent  Blue V (E 131). Published on 23 July 2010. Available at: 
http://www.efsa.europa.eu/en/dataclosed/call/ans100723.htm  
9  Call for scientific data on Patent  Blue V (E 131). Published on 6 June 2011. Available at: 
http://www.efsa.europa.eu/en/dataclosed/call/110606.htm Re-evaluation of Patent Blue V (E 131) as a food additive 
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Figure 1:  Structural formula of Patent Blue V 
Patent Blue V (E 131) is a dark blue powder, or in the form of granules. The melting point is >300°C. 
The substance is soluble in water and slightly soluble in ethanol.  
Several synonyms are in use. The most commonly used synonyms in published literature are for the 
calcium salt: C.I. Acid Blue 3, C.I. Food Blue 5, Carmine Blue V, C.I 42051; for the sodium salt: C.I 
Acid Blue 1, Acid Blue V, C.I. Food Blue 3, Carmine Blue VF, C.I 42045, Sulphan Blue, Brilliant 
Acid Blue VS, Blue VRS. 
2.2.  Specifications 
Specifications have been defined in the Directive 2008/128/EC
10 and new specifications according to 
Commission Regulation (EU) No 231/2012
11
According to Commission Regulation (EU) No 231/2012, Patent Blue V (E 131) consists essentially 
of the calcium or sodium compound of [4-(α-(4-diethylaminophenyl)-5-hydroxy-2,4-disulphophenyl-
methylidene)-2,5-cyclohexadien-1-ylidene] diethyl-ammonium hydroxide inner salt and subsidiary 
colouring matters, together with sodium chloride and/or sodium sulphate and/or calcium sulphate as 
the principal uncoloured components. The potassium salt is also permitted. 
 will apply from 1 December 2012. Specifications have 
also been defined by JECFA (JECFA, 2008) (Table 1). 
The purity is defined as content not less than 85 % total colouring matters, calculated as the sodium 
salt. The remaining 15 % may be accounted for by sodium chloride or sodium sulphate (but this is 
never mentioned explicitly),  ≤  2   % subsidiary colouring matters and total  ≤  0.5   % (3-hydroxy 
benzaldehyde, 3-hydroxy benzoic acid, 3-hydroxy-4-sulphobenzoic acid  and  N,N-diethylamino 
benzene sulphonic acid), ≤ 4 % leuco base,  ≤ 0.01  % unsulphonated primary aromatic amines and  ≤ 
0.2 % ether extractable matter, originating from the manufacturing process (Commission Regulation 
(EU) No 231/2012).  
Thus, if the existing specifications could be extended to include < 15  % sodium chloride and/or 
sodium sulphate as the principal uncoloured components, most of the material would be accounted for. 
                                                 
10 Commission Directive 2008/128/EC of 22 December 2008 laying down specific purity criteria concerning colours for use 
in foodstuffs. OJ L 6, 10.1.2009, p. 20–63. 
11  Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down specifications for food additives listed in 
Annexes II and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p 
1-295. Re-evaluation of Patent Blue V (E 131) as a food additive 
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Table 1:  Specifications for Patent Blue V according to Commission Regulation (EU) No 231/2012 
and JECFA (JECFA, 2008) 
Purity  Commission Regulation (EU)  
No 231/2012 
JECFA (2008) 
Assay  ≥ 85 %   ≥85 % 
Water insoluble matter  ≤ 0.2 %  ≤ 0.5 % 
Subsidiary colouring matters  ≤ 2.0 %  ≤ 2.0 % 
Organic compounds other than colouring 
matters : 
- 3-hydroxy benzaldehyde 
- 3-hydroxy benzoic acid 
- 3-hydroxy-4-sulphobenzoic acid 
- N,N-diethylamino benzene sulphonic acid 
 
 
total ≤ 0.5 % 
 
 
total ≤ 0.5 % 
 
Leuco base  ≤ 4.0 %  ≤ 4.0 % 
Unsulphonated primary aromatic amines  ≤ 0.01 %  
(calculated as aniline) 
≤ 0.01 %  
(calculated as aniline) 
Ether extractable matter  ≤ 0.2 % (from a solution pH 5)  ≤ 0.2% 
Arsenic   ≤ 3 mg/kg  - 
Lead   ≤ 2 mg/kg  ≤ 2 mg/kg 
Mercury  ≤ 1 mg/kg   
Cadmium  ≤ 1 mg/kg  - 
Chromium  -  ≤ 50 mg/kg 
 
The Panel noted that the JECFA specification for chromium is < 50 mg/kg whereas no specification 
for chromium is required in EC specifications. 
The Panel noted that the specifications on the purity of Patent Blue V (E 131) would permit 
concentrations of unsulphonated aromatic amines to be present in concentrations of up to 100 mg/kg 
Patent Blue V (E 131). Given the maximal allowed concentration of Patent Blue V (E 131) that can be 
added to food (500 mg/kg food), the concentration of these unidentified unsulphonated primary 
aromatic amines in food could be 50 μg/kg food.  
According to Commission Regulation (EU) No 231/2012, aluminium lakes of Patent Blue V (E 131) 
may be used and the above purity criteria for the pure substance also apply to the raw material from 
which the aluminium lake is produced. In addition, under neutral conditions the aluminium lake 
should contain no more than 0.5 % HCl-insoluble material and no more than 0.2 % ether extractable 
material. There are no additional specification requirements for the aluminium lake.  
JECFA does not give specifications for aluminium lakes of Patent Blue V  (E 131), other than 
reference to the General Specifications for Aluminium Lakes of Colouring Matters (JECFA, 2006). 
The Patent Blue V (E 131) used in the production process should comply with the specifications as 
given above, and the aluminium lake should contain not more than 2 % water-soluble chlorides and 
sulphates calculated as sodium salts, not more than 0.5  % HCl-insoluble matter, 0.2  % ether 
extractable matter, 3 mg arsenic/kg and 5 mg lead/kg. Unreacted aluminium oxide may also be present 
in the final product (not specified).  
The Panel noted that the aluminium lake of the colour could add to the daily intake of aluminium for 
which a tolerable weekly intake (TWI) of 1 mg aluminium/kg bw/week has been established (EFSA, 
2008) and that therefore specifications for the maximum level of aluminium in the lakes may be 
required. 
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2.3.  Manufacturing process 
According to information provided by industry, Patent Blue V (E 131) is manufactured, in a one-step 
reaction, by condensation and sulphonation of N,N-diethylaniline and 3-hydroxybenzaldehyde in 
acidic conditions (sulphuric acid) to produce the substance under leuco form. The leuco form is tested 
by thin layer chromatography (TLC). The leuco form is then solubilised in ammonia and oxidised with 
manganese dioxide in phosphoric acid. This reaction is controlled by high  pressure  liquid 
chromatography  (HPLC). The oxidised substance is neutralised with  sodium hydroxide and 
precipitated using either  hydrochloric acid and sodium chloride (to produce the sodium  salt) or 
hydrochloric acid and calcium chloride (to produce the calcium salt). This reaction is UV controlled. 
The precipitate is filtrated and the wet press cake so obtained is dried at 180°C. The dried product is 
further grinded or milled to obtain the product under powdered or granulated form. The substance is 
further standardised at a titre of 90 % with either sodium sulphate or sodium chloride (Fiorio Colori, 
2012b). 
Patent Blue V (E 131) may be converted to the corresponding aluminium lake under aqueous 
conditions by reacting aluminium oxide with the colouring matter. Undried aluminium oxide is usually 
freshly prepared by reacting aluminium sulphate or aluminium chloride with sodium carbonate or 
sodium bicarbonate or aqueous ammonia. Following lake formation, the product is filtered, washed 
with water and dried (Commission Regulation (EU) No 231/2012; JECFA, 2004). 
2.4.  Methods of analysis in food 
The most widely applicable methods to identify and quantify Patent Blue V (E 131) in foods and 
beverages employ high pressure liquid chromatography (HPLC) with diode array detection, after 
varying degrees of sample preparation depending on the matrix. Patent Blue V can be quantified in 
soft drinks from plant extracts and fruit juices, energy drinks, and vegetable nectars by degassing, 
filtering and direct injection into the HPLC with diode array detection. Recoveries range from 96.3 to 
98.5 % and the LOQ is 0.4 mg/l (Serdar and Knezevic, 2009). Beverages and powder mixes, fruit 
jellies, and hard candies, are extracted into hot water, filtered and concentrated. Cookies, cereal, 
wafers, chips, noodles, and soft candies are extracted into 25 % glacial acetic acid, centrifuged and 
chloroform defatted before being concentrated. After clean-up on a C18-Sep Pak cartridge, the 
extracts are evaporated to dryness and re-dissolved in HPLC mobile phase. Analysis again is by 
reverse phase HPLC with diode array detection giving an LOD of 0.12 mg/l for Patent Blue V (Harp 
et al., 2012). Similar HPLC methods have been reported by others (Kirschbaum et al., 2003; Minioti, 
et al., 2007; Yoshioka and Ichihashi, 2008; Dixit et al., 2010). Other less widely applicable approaches 
to the analysis of Patent Blue V have employed thin layer chromatography (Baranowska, 2004; 
Tuzimski and Woźniak, 2008), high performance thin layer chromatography (Tuzimski, 2011) and 
capillary electrophoresis (Patsovskii, 2004; Perez-Urquiza, 2000).  
2.5.  Reaction and fate in food 
No data on reaction and fate of Patent Blue V (E 131) in food are available. In general, the majority of 
colour additives are unstable in combination with oxidising and reducing agents in food. Since colour 
depends on the existence of a conjugated unsaturated system within the dye molecule, any substance 
which modifies this system (e.g. oxidising or reducing agents, sugars, acids, and salts) may affect the 
colour (Scotter and Castle, 2004). 
Data on stability of the Patent Blue V (E 131) in the dry state were provided by industry. Three 
different batches from three different productions were stored for up the 5 years at 25 °C and 60 % 
relative humidity and at 40 °C and 65 % relative humidity. The data show that the substance was fully 
stable under these conditions (Fiorio Colori, 2012b). 
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2.6.  Case of need and proposed uses 
Maximum Permitted Levels (MPLs) of Patent Blue V have been defined in the Commission 
Regulation (EU) No 1129/2011
12
Currently, Patent Blue V (E 131) is an authorised food colour in the EU with MPLs ranging from 50 to 
500 mg/kg in foods. For edible cheese rind and edible casings, Patent Blue V is authorised at quantum 
satis levels. 
 on food additives for use in foodstuffs. 
Table 2 summarises foods that are permitted to contain Patent Blue V (as part of group III food 
colours with combined maximum limit) and the corresponding MPLs as set by Commission 
Regulation (EU) No 1129/2011. 
Table 2:  MPLs of Patent Blue V in foods according to the Commission Regulation (EU) No 
1129/2011
13
Category 
number 
 
Category name 
Maximum 
Permitted Level 
(mg/kg or 
mg/l) 
01.4  Flavoured fermented milk products including heat-treated products  150 
01.6.3  Other creams (only flavoured creams)  150 
01.7.1  Unripened cheese excluding products falling in category 16 (only flavoured 
unripened cheese)  150 
01.7.3  Edible cheese rind  QS 
01.7.6  Cheese products (excluding products falling in category 16) (only flavoured 
unripened products)  100 
03  Edible ices  150 
04.2.1  Dried fruit and vegetables (only preserves of red fruit)  200* 
04.2.2  Fruit and vegetables in vinegar, oil, or brine (only preserves of red fruit)  200* 
04.2.3  Canned or bottled fruit and vegetables (only preserves of red fruit)  200* 
04.2.4.1  Fruit and vegetable preparations excluding compote (only mostarda di frutta and 
preserves of red fruit) 
200* 
05.2  Other confectionery including breath freshening microsweets (only candied fruit 
and vegetables)   200 
05.2  Other confectionery including breath freshening microsweets (except candied 
fruit and vegetables)  
300 
05.3  Chewing gum  300 
05.4  Decorations, coatings and fillings, except fruit-based fillings covered by 
category 4.2.4 (only decorations, coatings and sauces, except fillings) 
500 
05.4  Decorations, coatings and fillings, except fruit-based fillings covered by 
category 4.2.4 (only fillings) 
300 
06.6  Batters (only batters for coating)  500 
07.2  Fine bakery wares  200 
08.2.3  Casings and coatings and decorations for meat (only decorations and coatings 
except edible external coating of pasturmas) 
500 
08.2.3  Casings and coatings and decorations for meat (only edible casings)  QS 
09.2  Processed fish and fishery products including molluscs and crustaceans (only 
surimi and similar products and salmon substitutes) 
500 
                                                 
12 Commission Regulation (EU) No 1129/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 
of the European Parliament and of the Council establishing a Union list of food additives. The Panel noted that the 
Commission Regulation (EC) No 1129/2011 of 11 November 2011 will enter into force on June, 1
st 2013 but confirm the 
approved uses of Patent Blue V as a food additive as described in previous Council Directive No 94/36/EC of 30 June 1994 
on colours for use in foodstuffs. 
13 The description of the permitted uses of Patent Blue (E 131) has been amended to reflect the exact food category names 
reported in Commission Regulation (EU) No 1129/2011 (food categories 01.6.3, 01.7.1, 01.7.6, 05.2 and 06.6). The MPL 
value of category number 05.3 has been corrected from 100 mg/kg to 300 mg/kg, as in Commission Regulation (EU) No 
1129/2011. Re-evaluation of Patent Blue V (E 131) as a food additive 
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Category 
number  Category name 
Maximum 
Permitted Level 
(mg/kg or 
mg/l) 
09.3  Fish roe (only Sturgeons´ eggs (Caviar))  300 
12.2.2  Seasonings and condiments (only seasonings, for example curry powder, 
tandoori) 
500 
12.4  Mustard  300 
12.5  Soups and broths  50 
12.6  Sauces (including pickles, relishes, chutney and piccalilli; excluding tomato-
based sauces) 
500 
12.9  Protein products, excluding products covered in category 1.8 (only meat and 
fish analogues based on vegetable proteins) 
100 
13.2  Dietary foods for special medical purposes defined in Directive 1999/21/EC 
(excluding products from food category 13.1.5) 
50 
13.3  Dietary foods for weight control diets intended to replace total daily food intake 
or an individual meal (the whole or part of the total daily diet) 
50 
14.1.4  Flavoured drinks (excluding chocolate milk and malt products)  100 
14.2.3  Cider and perry (excluding cidre bouché)  200 
14.2.4  Fruit wine and made wine  200 
14.2.6  Spirit drinks as defined in Regulation (EC) No 110/2008 (except: spirit drinks 
as defined in article 5(1) and sales denominations listed in Annex II, paragraphs 
1-14 of Regulation (EC) No 110/2008 and spirits (preceded by the name of the 
fruit) obtained by maceration and distillation, London Gin, Sambuca, 
Maraschino, Marrasquino or Maraskino and Mistrà) 
200 
14.2.7.1  Aromatised wines (except americano, bitter vino)  200 
14.2.7.2  Aromatised wine-based drinks (except bitter soda, sangria, claria, zurra)  200 
14.2.7.3  Aromatised wine-product cocktails  200 
14.2.8  Other alcoholic drinks including mixtures of alcoholic drinks with non-
alcoholic drinks and spirits with less than 15 % of alcohol (only alcoholic drinks 
with less than 15 % of alcohol) 
200 
15.1  Potato-, cereal-, flour- or starch-based snacks (excluding extruded or expanded 
savoury snack products) 
100 
15.1  Potato-, cereal-, flour- or starch-based snacks (only extruded or expanded 
savoury snack products) 
200 
15.2  Processed nuts (only savoury-coated nuts)  100 
16  Desserts excluding products covered in categories 1, 3 and 4  150 
17.1  Food supplements supplied in a solid form including capsules and tablets and 
similar forms, excluding chewable forms 
300 
17.2  Food supplements supplied in a liquid form  100 
17.3  Food supplements supplied in a syrup-type or chewable form (only solid food 
supplements) 
300 
17.3  Food supplements supplied in a syrup-type or chewable form (only liquid food 
supplements) 
100 
* Maximum individually or for the combination of E 120, E 122, E 124, E 129, E 131, E 133 
 
2.7.  Reported use levels or data on analytical levels of Patent Blue V  
Summarised data on reported use levels in foods from industries and other sources 
Table 3 provides data on the use levels of Patent Blue V in foods as reported by industries and on 
analysed levels. Table 3 also shows the levels used for the refined exposure assessment identified by 
the Panel and based on data for several food categories in finished products reported by industries or 
analytical data from other sources (member states, scientific literature) or from the rules followed to 
deal with quantum satis (QS) authorisation as indicated in Annex A, figures 1 and 2.Re-evaluation of Patent Blue V (E 131) as a food additive 
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Table 3:  Summary of use levels of Patent Blue (E 131) as reported by industries or analytical data and levels used in the refined exposure assessment 
(mg/kg food or mg/l beverage)
14
Matching 
FoodEx Food 
codes 
 
Food items  MPL 
INDUSTRY  ANALYTICAL  Level used for calculation 
CIAA
(a)  CIAA
(a)  Ireland
(b)  UK
(c)  Cyprus
(d)  Slovakia
(e) 
  typical  max         
14.1.4  Non-alcoholic beverages  100  8-10  22*  <LOQ (1 mg/l) - 3  <LOD (0.1 mg/l) - 10  <LOD (0.2 mg/l) - 1.3  1.3  25 
14.2.3, 14.2.4  Fruit wines, cider and perry  200  3-10  10  <LOD (1 mg/l)     
 
10 
14.2.6  Spirituous beverages  200  0-20  60  <LOQ (1 mg/l)     
 
60 
04.2.1, 04.2.2, 
04.2.3, 04.2.4.1  Preserves of red fruits  200  10-100  150       
 
150 
05.4  Decorations and coatings  500  10-100  136        12.3-27.4 
mg/kg  140 
12.4  Mustard  300  5  5       
 
5 
01.4, 01.6, 16  Desserts including 
flavoured milk products  150  10  10       
 
10 
12.2, 12.6 
Sauces, seasonings, 
pickles, relishes, chutney 
and piccalilli 
500  6  6  <LOD (2-10 mg/kg)      20.66**  10 
05.2  Confectionary  300  5-200  300  <LOD (1 mg/kg) - 
158 
<LOD (0.5 mg/kg) - 
70  <LOD (0.2 mg/kg) - 8  1.4-27.1 
mg/kg  300 
03  Flavoured ices  150      <LOD (1-2 mg/kg)    <LOD (0.2 mg/kg) - 
19.9 
 
20 
 
* Tennant reported 24 mg/l for this category (Tennant, 2006) 
** Tabasco Green Pepper Sauce 
(a) CIAA, 2009; 
(b) FSAI, 2009; (c) FSA, 2002, 2003; 
(d)Cyprus State General Laboratory, 2010; 
(e)Slovakia, 2009 
For those categories where no reported use level was provided, the value presented in Table 1 (MPL) has been considered for the estimate calculation 
 
                                                 
14 The matching FoodEx food codes reported under item “desserts including flavoured milk products” were amended to include codes 01.4 and 01.6. The matching FoodEx food codes reported 
under item “sauces, seasonings, pickles, relishes, chutney and piccalilli” were amended to include code 12.2. Re-evaluation of Patent Blue V (E 131) as a food additive 
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2.8.  Information on existing authorisations and evaluations 
Patent Blue V (E 131) is authorised as a food additive in the EU under Commission Regulation (EU) 
No 1129/2011 on food additives for use in foodstuffs. Specific purity criteria on Patent Blue V have 
been defined in the EU Directive 2008/128/EC  and new specifications according to Commission 
Regulation (EU) No 231/2012 will apply from 1 December 2012. 
JECFA in 1970 established a temporary ADI of 0-1 mg/kg bw (JECFA, 1970). In 1975 JECFA 
withdrew the previously set temporary ADI (JECFA, 1975) due to the fact that information on the 
metabolism of the colour, a long-term study in a second species and a short-term study in a non-rodent 
species were lacking while JECFA required them in 1970. Up till now, JECFA has not allocated an 
ADI to Patent Blue V (E 131) (JECFA, 1982). 
The SCF allocated an ADI of 0-15 mg/kg bw to Patent Blue V in 1983 based on the no-adverse level 
of 1500 mg/kg bw/day, the highest dose tested in a long-term mouse study (SCF, 1983). 
The International Agency for Research on Cancer (IARC) evaluated Patent Blue V in 1987. It was 
concluded that Patent Blue V is carcinogenic in rats following its subcutaneous or intramuscular 
injection; it produced sarcomas at the site of repeated injections. No case reports or epidemiological 
studies were available. Patent Blue V has been considered in group 3, not classifiable as to 
carcinogenicity to humans (IARC, 1987). 
2.9.  Exposure assessment 
2.9.1.  Food consumption data used for exposure assessment 
Since  2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive 
Database) has been built from existing national information on food consumption at a detailed level. 
Competent authorities in the European countries provided EFSA with data on the level of food 
consumption by the individual consumer from the most recent national dietary survey in their country 
(cf. Guidance of EFSA ‘Use of the EFSA Comprehensive European Food Consumption Database in 
Exposure Assessment’ (EFSA, 2011b). 
Overall, the food consumption data gathered at EFSA were collected by different methodologies and 
thus direct country-to-country comparison should be made with caution. 
For calculation of chronic exposure, intake statistics have been calculated based on individual average 
consumption over the total survey period excluding surveys with only one day per subject. High level 
consumption was only calculated for those foods and population groups where the sample size was 
sufficiently large to allow calculation of the 95
th  percentile (EFSA, 2011b).  The Panel estimated 
chronic exposure for the following population groups: toddlers, children, adolescents, adults and the 
elderly. Calculations were performed using individual body weights. 
Thus, for the present assessment, food consumption data were available from 26 different dietary 
surveys carried out in 17 different European countries as mentioned in the Table 4: 
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Table 4:  Population groups considered for the exposure estimates of Patent Blue V 
Population  Age range  Countries with food consumption surveys covering more 
than one day 
Toddlers  from 12 up to and 
including 35 months of age 
Belgium, Bulgaria, Finland, Germany, Italy, Netherlands, 
Spain 
Children
15 from 36 months up to and 
including 9 years of age  
  Belgium, Bulgaria, Czech Republic, Denmark, Finland, 
France, Germany, Greece, Italy, Latvia, Netherlands, Spain, 
Sweden  
Adolescents  from 10 up to and 
including 17 years of age  
Belgium, Cyprus, Czech Republic, Denmark, France, 
Germany, Italy, Latvia, Spain, Sweden 
Adults  from 18 up to and 
including 64 years of age 
Belgium, Czech Republic, Denmark, Finland, France, 
Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Spain, 
Sweden, UK  
The elderly
15   Older than 65 years  Belgium, Denmark, Finland, France, Germany, Hungary, Italy 
 
Consumption records were codified according to the FoodEx classification system (EFSA, 2011a). 
Nomenclature from FoodEx classification system has been linked to the Food Classification System as 
presented in the Commission Regulation (EU) No 1129/2011, part D, to perform exposure estimates. 
2.9.2.  Exposure to Patent Blue V from its use as a food additive 
Exposure to Patent Blue V from its use as a food additive has been calculated by using (1) MPLs as 
listed in Table 2 and (2) data on reported use levels or data reported on analytical levels as listed in 
Table 3 including data following the rules for QS regulations (refined exposure assessment), both 
combined with national consumption data for the five population groups (Table 4). 
High level exposure (typically 95
th percentile of consumers only) was calculated by adding the 95
th 
percentile of exposure from one food group (i.e. the one having the highest value) to the mean 
exposure resulting from the consumption of all other food groups.  
This is based on the assumption that an individual might be a high level consumer of one food 
category and would be an average consumer of the others. This approach has been tested several times 
by the Panel in the re-evaluation of food colours and has shown reasonable correlation with high level 
total intakes when using the raw food individual consumption data. Therefore, this approach was 
preferred for the calculations based on the MPLs and maximum reported use levels in order to avoid 
excessively conservative estimates.  
However, the Panel notes that its estimates should be considered as being conservative as it is assumed 
that all processed foods contain Patent Blue V added at the MPLs or the maximum reported use levels. 
Table 5 summarises the estimated exposure to Patent Blue V from its use as a food additive of all five 
population groups. 
 
 
 
                                                 
15 The terms “children” and “the elderly” correspond respectively to “other children” and the merge of “elderly” and “very 
elderly” age groups in the EFSA Guidance on the ‘Use of the EFSA Comprehensive European Food Consumption 
Database in Exposure Assessment’ (EFSA, 2011b). Re-evaluation of Patent Blue V (E 131) as a food additive 
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Table 5:  Summary of anticipated exposure to Patent Blue V from its use as a food additive using 
MPLs and reported use levels or analytical data on use levels in five population groups 
(mg/kg bw/day) 
  Toddlers  Children  Adolescents  Adults  The elderly  
  (12-35 
months)  (3-9 years)  (10-17 years)  (18-64 
years)  (>65 years) 
Estimated exposure using MPLs 
•  Mean  
•  High level
16
 
 
1-4.5 
2.9-7.5 
 
1.1-3.6 
2.4-7 
 
0.5-1.8 
1.3-3.7 
 
0.3-1.4 
0.9-2.9 
 
0.2-0.6 
0.6-1.5 
Estimated exposure using 
reported use levels or analytical 
data 
•  Mean  
•  High level
16 
 
 
 
0.2-1.5 
0.6-2.7 
 
 
 
0.4-1.2 
1-2.4 
 
 
 
0.3-0.7 
0.7-1.7 
 
 
 
0.1-0.5 
0.4-1 
 
 
 
0.04-0.3 
0.1-0.8 
 
2.9.3.  Main food categories contributing to exposure to Patent Blue V using MPLs 
Table 6:  Main food categories contributing to exposure to Patent Blue V using MPLs and number 
of surveys (between brackets) in which each food category is contributing 
   Toddlers  Children  Adolescents  Adults  The 
elderly  
Food Categories  % contribution to total exposure (Number of Surveys) 
1.4. Flavoured fermented milk 
products including heat treated 
products 
22-68 (6)  13-32 (9)  12-13 (3)  14-29 (2)  16-27 (2) 
1.6. Cream          12-14 (3) 
1.7.1. Unripened cheese 
(excluding category 16)    14 (1)  15 (1)  22 (1)  22 (19) 
3. Edible ices  14 (1)  11 (2)       
5.2.1. Other confectionery with 
added sugar    10 (1)       
7.2. Fine bakery wares  13-50 (5)  11-45 (13)  12-37 (11)  11-34 (12)  10-31 (6) 
9.2. Processed fish and fishery 
products including mollusks and 
crustaceans 
  15 (1)       
12.2. Herbs, spices, seasonings      14 (1)     
12.5. Soups and broths    13 (1)  12 (1)  16 (1)  16 (1) 
12.6. Sauces  11 (1)  11-23 (8)  14-28 (7)  12-29 (10)  11-26 (5) 
14.1.4.1. Flavoured drinks with 
sugar  13-21 (4)    15-55 (7)  11-48 (12)  12-39 (3) 
14.1.4.2. Flavoured drinks with 
sweeteners  15 (1)    20-27 (2)  11-37 (3)   
14.2. Alcoholic beverages, 
including alcohol-free and low-
alcohol counterparts 
      11-13 (2)   
16. Desserts excluding products 
covered in category 1, 3 and 4  12-15 (2)         
 
                                                 
16 Typically 95
th percentile of consumers only. Re-evaluation of Patent Blue V (E 131) as a food additive 
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2.9.4.  Main food categories contributing to exposure to Patent Blue V using reported use 
levels or reported data on analytical levels 
Table 7:  Main food categories contributing to exposure to Patent Blue V using reported use levels 
or reported data on analytical levels and number of surveys (between brackets) in which 
each food category is contributing 
   Toddlers  Children  Adolescents  Adults  The elderly 
Food Categories  % contribution to total exposure (Number of surveys) 
1.4. Flavoured fermented milk 
products including heat treated 
products 
12-28 (2)         
1.7.1. Unripened cheese 
(excluding category 16)  11-18 (2)  14 (1)  19 (1)  14-28 (2)  11-27 (3) 
5.2.1. Other confectionery with 
added sugar  11 (2)  12-32 (6)  16-28 (2)  26-28 (2)  15-17 (2) 
7.2. Fine bakery wares  15-71 (7)  10-70 (15)  19-62 (11)  15-64 (14)  31-59 (6) 
9.2. Processed fish and fishery 
products including mollusks and 
crustaceans 
16-19 (2)  13-22 (5)  12-15 (3)  19 (1)   
12.5. Soups and broths  17 (1)  13-26 (2)  24 (1)  14-31 (2)   
14.1.4.1. Flavoured drinks with 
sugar  11-16 (2)  10-31 (11)  11-40 (7)  11-27 (2)  15-25 (2) 
14.1.4.2. Flavoured drinks with 
sweeteners  12 (1)    12-18 (2)  12-38 (8)  15-25 (2) 
14.2. Alcoholic beverages, 
including alcohol-free and low-
alcohol counterparts 
      11-12 (2)   
15.1. Potato-, cereal-, flour- or 
starch-based snacks  18 (1)    12-14 (2)     
17. Food supplements as defined 
in Directive 2002/46/EC 
excluding food supplements for 
infants and young children 
        17 (1) 
 
3.  Biological and toxicological data 
Patent Blue V (E 131) has been evaluated previously by JECFA in 1970 and 1975, and the SCF in 
1983. It was also evaluated by TemaNord (2002). The present opinion briefly reports the major studies 
included in these evaluations and describes the additionally, reported new literature in more detail. 
3.1.  Absorption, distribution, metabolism and excretion 
JECFA (1975) describes one study regarding the toxicokinetics of Patent Blue V (E 131). In this 
study, after intravenous injection in rats (0.5 ml, 50 mg/ml aqueous solution) and subcutaneous 
injection in man (no details), the colour was excreted in the urine during a 12-hour observation period 
following injection (Truhaut, 1962). 
The SCF (1983) states that Patent Blue V (E 131) is poorly absorbed by rats and dogs after single oral 
administration, and that the nature of the metabolites was not determined. 
An in vitro study has been performed in 2011 (Guerbet/Eurofins, 2011) in order to measure the 
metabolism of Patent Blue V (E 131) in hepatic microsomes from rats and humans. Patent Blue V (1, 
In vitro data  Re-evaluation of Patent Blue V (E 131) as a food additive 
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5, 10 and 100 μM), was added in the presence of 150 μg microsomal proteins (for the concentrations 
10 and 100 μM) and 500 μg microsomal proteins (for the concentrations 1 and 5 μM). Patent Blue V 
used in this assay was in accordance with the EU specifications for this food colour (purity  ≥ 85 %).  
Omeprazole,  a  known metabolic substrate for human and rat microsomal enzymes,  was used as 
positive control. The Omeprazole concentrations tested were 0.58, 1, 5, and 100 μM in the same 
experimental conditions as those used for Patent Blue V (E 131). After incubation of 1 μM or 5 μM 
Patent Blue V, no metabolism was observed with either human or rat microsomes. After incubation of 
Patent Blue V at 10 μM, mean metabolism observed was 1 % when incubated with human microsomes 
and no metabolism was observed for rat microsomes. After incubation of Patent Blue V at 100 μM, 
mean metabolism observed was 3.4 % when incubated with human microsomes and 0.35 % for rat 
microsomes. After incubation of 0.58 μM Omeprazole, mean metabolism observed was 68 % for 
human microsomes and 96 % for rat microsomes, validating the enzyme activity of the microsomes at 
this concentration. Based upon these in vitro results, the authors conclude that Patent Blue V is not 
metabolised at concentrations of 1 to 100 μM in the presence of human or rat hepatic microsomes. 
In vivo data  
In preliminary studies in rats  (LEMM, 1978a), only low levels of radioactivity (representing a 
maximum of less than 0.03 % of the dose) were detected in serial blood samples taken at intervals of 
up to 72 hours from males given a range of single oral doses of 0.34 and 1.21 (
14C) Patent Blue V 
mg/kg bw (position of labelling  not specified). Although the peak concentration of radioactivity 
(which occurred within one hour of dosing) fell by 46-84 % in 24 hours, radioactivity was detectable 
in the blood at 72 hours. Following a single i.v. injection in rats of about 0.35 (
14C) Patent Blue V 
mg/kg bw (position of labelling not specified), elimination from the blood was rapid. Serial blood 
sampling revealed that the levels of radioactivity after one hour were only about 13-14 % of the initial 
value. At 4 hours these had fallen to 3-4 % and at 24 hours this was 1 %. The majority of radioactivity 
was excreted in the faeces (more than 90 % within 24 hours) but, in contrast to the mouse in which 
urinary excretion amounted to 24 % of the i.v. dose at 24 hours, only up to 2 % of the radioactivity 
injected appeared in the urine of the rat within this time-period. Less than 0.1 % of the administered 
dose of radioactivity was detected in expired air.  Less than 0.5 % of the administered dose was 
excreted in the urine, whilst over 80 % appeared in the faeces; for both routes of administration, the 
majority was excreted within 24 hours. At 72 hours, less than 0.5 % of the dose was detected in the 
carcass.  Analysis of the major organs of rats 72 hours or 96 hours after oral administration of 
radiolabelled Patent Blue V or 72 hours following i.v. dosing indicated a wide distribution. Higher 
levels of radioactivity were, as expected, associated with the gastrointestinal tract and organs involved 
in excretion. In addition, concentrations of radioactivity were several folds higher in the thyroid, 
compared to most other tissues in animals dosed by both the i.v. and oral routes (LEMM, 1978a; 
BIBRA, 1982). 
Rats 
More detailed studies, where groups of male and female Sprague-Dawley rats were given oral doses 
between 1.6 and 3.2 mg (
14C) Patent Blue V/kg bw, and then killed at intervals of up to 48 hours, were 
in agreement with the preliminary findings (LEMM, 1978b). A kinetic study showed that there were 2 
phases of elimination from the blood with half-lives of 15 minutes and 39 hours, respectively. Low 
levels of activity remained in the carcass after 48 hours; again slightly elevated concentrations were 
noted in the thyroid compared to other tissues. In 6 male rats given oral doses of 1 to 1.5 mg (
14C) 
Patent Blue V/kg bw, a total of 93 % of the dose appeared in the faeces within 24 hours. Radioactivity 
extracted from the faeces in these studies was in the form of unchanged colour. Less than 0.5 % of the 
radioactivity was excreted in the urine (most within the first 4 hours), and of this, 20-50 % was as the 
unchanged colour. In addition, 2  substances representing 30-32  % and 12-14  % of the urinary 
radioactivity and 3 minor components were detected but not identified. The excretion in both urine and 
faeces appeared to be biphasic. The early rapid elimination of the majority of the radioactivity was 
followed by a much slower excretion of the remainder (possibly as a result of coprophagy) (LEMM, 
1978b, c; BIBRA, 1982). Re-evaluation of Patent Blue V (E 131) as a food additive 
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Periodic collection of bile at intervals for up to 96 hours, from 2 cannulated male rats given a single 
oral dose of 0.81 or 0.89 mg/kg bw (
14C) Patent Blue V revealed biliary excretions of 6.1 % of the 
doses within 54 hours. The peak in the radioactivity occurred within the first three hours, with little 
excretion occurring after 12 hours. The radioactivity present was in the form of unchanged colour. The 
total radioactivity excreted in the bile and urine and remaining in the carcass indicated that around 6.7 
% and 4.4 % of the dose was absorbed (LEMM, 1978b; BIBRA, 1982). 
The relatively low absorption after oral administration was confirmed by analysis of the organs from 
rats given oral doses 1.8 - 3.2 mg/kg of (
14C)radiolabelled Patent Blue V, and killed at intervals of up 
to 48 hours, and from rats given 0.87 - 1.18 mg/kg and killed at 120 hours. Wide tissue distribution 
was again observed. In tissues other than the gastrointestinal tract, the findings suggest that about 10 
% of the orally administered dose was present at 0.5 hour. This fell to 2 % by 24 hours and 0.2 % by 
48 hours. Small amounts of the dose were present in the carcass at 72 hours and less than 0.1 % of the 
dose was present at 120 hours. There was some evidence for preferential accumulation of radioactivity 
in the thyroid; concentrations were several folds higher than in many other tissues throughout the 
study.  
Autoradiographs of 3 rats treated orally with 0.48, 8.75 or 9.08 mg (
14C) Patent Blue V/kg bw and 
killed at 1,  24 and 48 hours after dosing, confirmed that the absorbed radioactivity was widely 
distributed (LEMM, 1978b; BIBRA, 1982). 
(
14C) Radiolabeled Patent Blue V (label position not specified) complying with JECFA specifications 
was used in studies in which 2 groups of 1 male and 1 female 8-month-old Beagle dogs received 
single oral doses of 0.23 and 0.25 mg/kg bw or single i.v. doses of 0.11 mg/kg, respectively (LEMM, 
1978d; BIBRA, 1982). Excretion following i.v. injection was in 2 phases, with half-lives in the blood 
of 2.7 and 36.5 hours, respectively. Less than 1 % of the initial concentration of radioactivity remained 
in the blood at 24 hours. Totals of 3.3 and 15.6 % of the amount injected intravenously were excreted 
in the urine within 72 hours, the majority being excreted within 24 hours. 14.8 % and 89.3 % of the 
injected doses, were excreted in the faeces within 72 hours, thus it was likely that biliary excretion had 
occurred. 
Dogs 
After oral dosing, low levels of radioactivity (which peaked after 1.25 hours at concentrations 
representing about 0.002 % of the dose/g blood) were detected in the blood. Examination of the blood 
kinetics revealed a slower elimination rate than when the dogs were dosed by the i.v. route, involving 
3 compartments with half lives of 0.3 hour, 2.7 hours and 33.3 hours. Delayed clearance of residual 
levels of radioactivity was again noted. In total, 1.3 and 1.4 % of the dose were excreted in the urine in 
24 hours, whilst 41.1  % and 77.6  % were recovered in the faeces. Up to 12  % of the dose of 
radioactivity was recovered from the cage. 
Chromatographic study of the faeces and urine from animals dosed by both routes indicated that little 
of the colour was metabolised, but no attempt was made to identify the metabolites present. 
Radioactivity remained in the tissues after 72 hours (1 % of the injected dose and 0.1 % of the oral 
dose); no specific accumulation in the thyroid was noted, but concentrations of radioactivity in the 
testes were higher than the other tissues (excluding those involved in excretion) (LEMM, 1978d,c). 
Overall, in vitro data showed that Patent Blue V was  not metabolised  by rat or human hepatic 
microsomal enzymes.  Data available on the absorption, distribution, metabolism and excretion of 
Patent Blue V after oral administration in rats and dogs showed that Patent Blue V has low absorption 
and limited systemic availability. It was mainly excreted in faeces. 
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3.2.  Toxicological data 
3.2.1.  Acute oral toxicity 
JECFA described a study by Truhaut (1962) in which acute toxicity studies were conducted with 
Patent Blue V in mice and rats. The oral LD50 values in mice and rats were greater than 3000 and 5000 
mg/kg bw respectively. 
3.2.2.  Short-term and subchronic toxicity 
In a study in 3 cats, the animals received daily oral doses of 250, 500 and 750 mg (5 % aqueous 
solution) of the colour. Without presenting details on which parameters were examined, it is stated that 
no abnormalities were found (Truhaut, 1962). 
Cats 
Patent Blue V (calcium salt) was incorporated into the diet of groups of 4 male and 4 female 6- to 8-
month old Beagle dogs for 13 weeks at levels of 0, 0.3 and 1 %. These levels, which were shown to be 
of acceptable palatability in preliminary studies, provided daily intakes of about 0, 80 and 280 mg/kg 
bw/day (IFREB, 1978a; BIBRA, 1982). No mortality occurred during the study. Group body weights 
appeared to be slightly reduced in the treated animals, but differences were small and food and water 
consumption were not affected by treatment. At the end of the study, ocular examination, urine and 
blood biochemistry revealed no treatment-related effects, apart from a tendency to reduced creatinine 
clearance. In both groups of dosed females, at week 13 the reduction in creatinine clearance was 
significantly reduced (Student’s t test, P < 0.05) compared to controls. However, the relationship was 
not strictly dose-related and the values were considered by the authors to remain within normal limits. 
According to the  authors of the  BIBRA (1982) report,  the  No-Observed-Adverse-Effect  Level 
(NOAEL) of this study was 280 mg/kg bw/day, the highest dose tested. The Panel agreed with this 
conclusion. 
Dogs 
3.2.3.  Genotoxicity 
JECFA did not address the genotoxicity of Patent Blue V (JECFA, 1970; 1975). The SCF mentioned 
that in vitro mutagenicity studies were available to the Committee (SCF, 1983). 
Patent Blue V did not demonstrate any evidence of mutagenic activity in strains of tryptophan-
requiring Escherichia coli and histidine-requiring Salmonella typhimurium (4 strains) both with and 
without metabolic activation (Viola and Nosotti, 1978; Gubbini et al., 1975; Haveland-Smith and 
Combes, 1980).  
In vitro studies 
An Ames test with Patent Blue V was performed in 2010 according to the OECD guideline for testing 
of chemicals No. 471 (Guerbet/Ricerca, 2010). The reported purity of Patent Blue V used in this assay 
was 86 %, in compliance with the EU specifications for this food colour (purity ≥ 85 % ). 
Five histidine-dependent strains of S. typhimurium (TA98, TA100, TA1535, TA1537 and TA102) 
were used to evaluate the mutagenic potential of Patent Blue V, both in the absence and presence of rat 
liver S9 metabolism. The study was carried out using both the plate incorporation and the pre-
incubation methods. Patent Blue V was tested as a dark blue solution in water for injection. 
The first experiment, using the plate incorporation method was carried out using the dose range of 52-
5000  μg/plate,  both  in  the  absence  and  presence  of  rat  S9  metabolism.  Following  treatment,  no 
precipitation and cytotoxicity (reduction in the number of revertants and/or thinning of the background Re-evaluation of Patent Blue V (E 131) as a food additive 
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lawn) were noted in the absence or in the presence of metabolic activation. Statistically and 
biologically significant increases in the number of revertants were observed only with the TA98 tester 
strain in the presence of metabolic activation. 
On the basis of the results obtained a second experiment using the pre-incubation method was carried 
out in the dose range of 492-5000  μg/plate,  both in the absence and presence of rat liver S9 
metabolism. Following treatment, no precipitation or cytotoxicity were noted in the absence or in the 
presence of metabolic activation. Statistically and biologically significant increases in the number of 
revertants were confirmed with the TA98 tester strain in the presence of metabolic activation. 
The Panel noted that the positive outcome obtained in the presence of metabolic activation and at 
higher dose levels only, strongly indicates that mutagenicity could have been caused by the presence 
of impurities given the low purity of the test item (86 %) and the absence of reported metabolic 
conversion of Patent Blue V. 
In the study by Masannat et al. (2009), which aimed to investigate potential genotoxicity of Methylene 
Blue, Patent Blue V and Indigo Carmine commonly used in sentinel node biopsies, Patent Blue V was 
assessed for potential DNA damaging properties in an in vitro alkaline Comet assay in breast epithelial 
MCF-7 and HB-2 cell lines. The enzyme Fapy-DNA glycosylase (FpG) was also incorporated in the 
Comet assay to enable detection of additional oxidative DNA damage. Treatments were performed for 
5 minutes at the highest dose level of 25 mg/ml; the same dose level used in clinical practice. Three 
lower dose levels (0.1,1 and 10 mg/ml) were also employed. Results obtained showed dose-related and 
statistically significant increases of “tail DNA”. However, the Panel observed that the 2 higher dose 
levels employed largely exceeded the highest recommended dose-levels (5 mg/ml) to be used in 
mammalian cells in vitro (Seeberg et al., 1988; Galloway et al., 1994; OECD guidelines for testing of 
chemicals No. 473 and 487). The results observed at the two lower levels, although significant, were 
within the range of variability of untreated controls. On this  basis,  the study was judged to be 
unreliable.  
In an unpublished study report, the mutagenic potential of Patent Blue V was assessed in the in vitro 
mammalian cell gene mutation assay using L5178Y (Tk
+/-) mouse lymphoma cells (Guerbet/Ricerca, 
2011a). The study was conducted in compliance with the OECD guideline No. 476 and the ICH 
guidelines S2A and S2B. The reported purity of Patent Blue V was 86 % which is in compliance with 
the EU specifications for this food colour (purity  ≥ 85  %). Long treatment (approximately 24 hours) 
without metabolic activation and short treatment (approximately 4 hours) both in the absence and 
presence of rat liver S9 metabolism were performed. Replicate cultures were set up at each 
experimental point. 
Treatments were performed at dose levels ranging from 0.86 to 2500 μg/ml for approximately 24 
hours in the absence of S9 metabolism and at dose levels ranging from 246 to 2500 μg/ml and 43 to 
2500 μg/ml for approximately 4 hours in the absence and presence of S9 metabolism respectively. No 
presence of detectable precipitation was observed at any experimental point. 
No cytotoxicity (decrease in the relative survival and/or in the relative total growth) was noted at any 
tested dose level, in the absence or in the presence of metabolic activation. No statistically or 
biologically significant increases in the mutant frequency were noted up to the maximum tested dose 
level of 2500 μg/ml at any treatment time in the absence or presence of metabolic activation. 
Overall, from the previous study the Panel considered that Patent Blue V did not show mutagenic 
potential in mammalian cells at doses up to 2500 µg/ml. The Panel noted that according to the report it 
was not possible to test higher doses of Patent Blue V in this assay due to the reported limit of 
solubility of 100 mg/ml in aqueous solvent. However, the Panel noted that the use of culture medium 
as direct solvent for Patent Blue V could have allowed to reach the upper limit of concentration (5000 
µg/ml) indicated by the relevant OECD guideline (OECD 476) and possibly the detection of impurities Re-evaluation of Patent Blue V (E 131) as a food additive 
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showing  mutagenic  effect in bacteria. Therefore, the Panel considered  the results of this assay 
inconclusive. 
In the study by Misra et al. (1986), which aimed to investigate potential in vivo genotoxicity of 3 
commonly used dyes, Patent Blue V was assessed for potential clastogenicity in an in vivo bone 
marrow micronucleus assay in Swiss male mice. The test item used was identified as Blue VRS 
(purity not reported), Acid Blue 1 or Food Blue 3 with CAS no. 129-17-9 and a molecular weight of 
566.7 g/mol. Purity was not reported. The test compound was administered to groups of 3 mice by 2 
intraperitoneal injections 24 hours apart at dose-levels of 100, 200, 400 and 800 mg/kg bw. Animals 
administered 800 mg/kg of the test item died shortly after treatment. Surviving animals were sacrificed 
6 hours after the second injection and a total of 30 slides from each animal group (i.e. 10 slides for 
each animal) were prepared and subsequently stained and scored at microscope magnification x 1000. 
A minimum number of 750 erythrocytes (both polychromatic and normochromatic erythrocytes) were 
scored, when possible, from each slide. Results obtained indicated that the test item induced marked 
increases in the percentage of cells with micronuclei at the higher dose level both in the polychromatic 
and normochromatic erythrocytes. However, the Panel noted that marked increases in micronucleated 
normochromatic erythrocytes cannot be attributable to test compound genotoxicity based on  the 
experimental protocol applied (30 hour sampling time) due to the physiology of erythrocytes 
maturation following expulsion of nuclei. Their appearance is not expected not earlier than 30 hours 
and therefore the presence of micronucleated normochromatic erythrocytes cannot be attributed to 
treatment with the test substance but to a previous exposure to genotoxic compounds or an unhealthy 
status of animals. Therefore the outcome of the study generates strong doubts about the reliability of 
scoring of micronucleated cells. On these bases the study has been judged unreliable. 
In vivo studies  
In the study by Durnev et al. (1995) which aimed to investigate potential in vivo genotoxicity of 6 
food colours, Patent Blue V (purity unknown) was assessed for potential clastogenicity in an in vivo 
bone marrow chromosome aberration assay in C57Bl6 mice. The test item was administered by oral 
gavage at daily dose levels of 0.08 and 0.8 mg/kg bw for 5 days. Animals were sacrificed 6 hours after 
the administration of the last dose level. In the last 2 hours mice also received colchicine at 2.5 mg/kg 
bw to accumulate cells in metaphases. A minimum number of 100 well spread metaphases were 
scored for each animal in the control and treated groups. Results obtained indicated that Patent Blue V 
did not induce statistically significant increases of chromosomal aberrations in the mouse bone 
marrow cells erythrocytes under the reported experimental conditions. However, the Panel noted that 
mitotic indices, important to detect bone marrow cytotoxicity, were not evaluated and that scoring of 
aberrations did not follow internationally recognised methods as described in the current literature.  
In an unpublished study report, the mutagenic potential of Patent Blue V was assessed in the in vivo 
bone marrow micronucleus assay in Sprague-Dawley rats (Guerbet/Ricerca, 2011b). The study was 
conducted in compliance with the OECD guideline 474. The reported purity of Patent Blue V used in 
this assay was 86 %, which is in compliance with the EU specifications for this food colour (purity  ≥ 
85 % ). On the basis of a preliminary experiment in which mortality was observed at 600 mg/kg bw, 
the study was carried out using groups of 5 male and 5 female rats administered dose levels of 75, 150 
and 300 mg/kg, by a single intravenous injection. Saline (0.9 % NaCl) was used as vehicle. Animals 
were sacrificed 24 and 48 hours after administration. Clinical signs were noted only at the highest dose 
level of 300 mg/kg bw and consisted of irregular breathing and/or lowered activity in some animals. 
When compared to the negative control group (0.9 % NaCl), no biologically significant decreases in 
the polychromatic/normochromatic erythrocytes ratio (PCEs/NCEs) were  noted in any animal 
treatment groups. For either sex or both sexes combined, when compared to the negative control group 
(0.9  % NaCl), no biologically significant increase in the mean frequencies of micronucleated 
polychromatic erythrocytes (MNPCEs) was noted in the animal groups treated with Patent Blue V up 
to the highest dose level of 300 mg/kg. The authors concluded that under the reported experimental 
conditions Patent Blue V did not prove to induce micronuclei in rat bone marrow erythrocytes. The 
Panel agreed with this conclusion. Re-evaluation of Patent Blue V (E 131) as a food additive 
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In  an  unpublished  study  report,  the DNA damaging capabilities of Patent Blue V (E 131) were 
assessed in the in vivo single cell gel/Comet assay in rats (Fiorio Colori, 2012a). The study was 
conducted in compliance with the internationally agreed protocols, since no OECD test guidelines are 
yet available and in compliance with the OECD principles of Good Laboratory Practice (GLP) as 
revised in 1997. The reported purity of Patent Blue V used in this assay was 90 % and therefore in 
compliance with the EU specifications for this food colour (purity  ≥ 85  % ). Patent Blue V (E 131) 
was examined for genotoxic properties by  evaluating the induction of DNA damage in cell 
suspensions isolated from liver, jejunum/ileum and peripheral blood of rats after in vivo treatment 
using the alkaline (pH>13) version of the Comet Assay. In the main experiment, only male animals 
were treated since no substantial inter-sex differences in toxicity were observed. Groups of 5 Sprague-
Dawley male rats were treated twice at 24 hour intervals with the vehicle only (sterile distilled water 
of injectable grade), or Patent Blue V (E 131) at the dose levels of 500, 1000 and 2000 mg/kg/day. The 
highest dose level represents the maximum dose level to be used for non-toxic compounds. Ethyl 
methanesulphonate (EMS),  at 200 mg/kg/day  served as positive control. Animals were sacrificed 
approximately 3-4 hours after the second dosing. Peripheral blood and cell suspensions isolated from 
liver and jejunum/ileum were embedded in agarose gel on microscope slides.  No statistically 
significant increases in tail moment and tail intensity values compared with the vehicle control values 
were observed at any dose-level in the treated groups. The authors concluded that Patent Blue V (E 
131) does not induce any effect on DNA migration in rat liver, jejunum/ileum and peripheral blood 
after in vivo treatment under the reported experimental conditions. The Panel agreed with this 
conclusion. 
According to new studies provided by industry on request of EFSA, the Panel considered that Patent 
Blue V (E 131) (at purity level > 90 %) is not of concern with respect to genotoxicity. 
3.2.4.  Chronic toxicity and carcinogenicity 
In 1983, the SCF allocated an ADI of 15 mg/kg bw/day based on the no-adverse level of 1500 mg/kg 
bw/day in the following mouse study (SCF, 1983). 
Mice 
A combined reproductive toxicity and long-term toxicity study has been performed in mice. Groups of 
65 male and female mice were given diets containing 0.1, 0.3 or 1 % Patent Blue V (equivalent to 150, 
500 and 1500 mg/kg bw/day) for 9 weeks prior to mating and throughout mating, gestation and rearing 
of their offspring (F1 generation) (IFREB, 1981, as referred to by BIBRA, 1982). 
According to BIBRA (1982), groups of 50 (treatment groups) and 100 (control) mice of each sex were 
selected from the offspring (1 male plus 1 female from each litter) and given the same treatment as 
their parents for 21 months (males) or 23 months (females). The colour used in this study complied 
with the requirements of the JECFA specification. 
There were no treatment-related behavioural or clinical findings. Growth rates and food consumption 
were roughly comparable in all groups, but the body weights of the males in the top dose group were 
frequently significantly reduced (Student’s t-test). The high-dose males demonstrated a slightly 
increased mortality; by the end of the study, 60 % of controls compared to 76 % of the high-dose 
males, had died.  
Haematological analyses carried out on 20 animals of each sex from the high-dose and control groups 
at 3, 6, 12 and 18 months, and on all surviving animals at the end of the experiment, did not identify 
any consistent effects, apart from significantly reduced values for haemoglobin, haematocrit and red 
blood cell counts detected in the males (P < 0.01 % in each case) and females (P < 0.5) from the high-
dose group at 3 months and at the end of the study in the males. These values were not significantly 
reduced at the other examinations. A significant (P < 0.01) reduction in reticulocyte count and an 
increase in the total number of white blood cells in the high-dose males (P < 0.01) and females (P < Re-evaluation of Patent Blue V (E 131) as a food additive 
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0.5) were observed at 12 months only. After 21 months, there was a highly significant reduction in the 
lymphocyte and total leucocyte counts in males and the polymorph count was significantly elevated (P 
< 0.01), but their distribution was random, and appeared unrelated to treatment (more details were not 
available). 
Comparison of the absolute and relative weights of the organs revealed a highly significant reduction 
(P < 0.01) in the relative and absolute liver weights of the males in the intermediate dose group, but 
not at the top dose. The absolute weight of this organ was also significantly reduced (P < 0.01) in the 
females of the intermediate dose group.  
Increases in the absolute (P < 0.01) and relative (P < 0.05) kidney weights of the females were 
reported at the intermediate dose, but at the high-dose level only the absolute weight of the kidneys in 
females  was statistically significant (P < 0.05). Females in the 2  higher dose groups exhibited 
increased relative heart weights (P < 0.01), and females in the highest dose group had increased caecal 
weights (full, P < 0.05; and empty, P < 0.01). 
Full histopathological examination of a comprehensive selection of organs and tissues from the high-
dose and control groups and gross lesions seen at autopsy in the intermediate and low-dose groups 
revealed a range of non-neoplastic and neoplastic pathology. The observed non-neoplastic lesions 
which frequently occurred in both control and treatment groups (mainly involving the lungs, kidneys 
or liver) or were isolated occurrences, were not considered to be related to the administration of Patent 
Blue V.  
A number of neoplastic lesions occurred in the treated but not in the control animals, such as 
squamous cell carcinoma (1 animal in each dose), osteosarcoma (1 animal at each dose), 
nephroblastoma (1 male at intermediate dose), adrenocortical adenoma (1 male at lowest and 
intermediate doses, 2 males at highest dose), adrenocortical carcinoma (1 male at highest dose), 
adenocarcinoma of the thymus (1 female at intermediate dose), adenoma of mammary gland (1 female 
at intermediate and  highest doses). These were mainly isolated findings, of commonly occurring 
tumours showing no dose-response relationship. Based on these arguments, the Panel concluded that 
these neoplastic lesions were not indicative of a carcinogenic effect. In the absence of the full study 
report, the Panel considered that the haematological effects observed at the highest dose tested are 
biologically  significant. Therefore,  the Panel  considered  that  a  NOAEL of 500  mg/kg bw/day 
(intermediate dose tested) can be derived from this study, based on growth reduction and alterations of 
haematological parameters reported at the highest dose tested, mainly in males. 
In 1970, JECFA based its temporary ADI of 1 mg/kg bw/day on the following study.  
Rats 
Rats (30 animals/sex) were given in their diet 10 000 mg of Patent Blue V/kg diet, equivalent to 500 
mg/kg bw/day of the colour for their life-span. The colour used was pure (no impurities were found by 
paper chromatography studies)  (Truhaut,  1962). The average life-span of treated animals was 24 
months and the last animal died at an age of 37.5 months. Forty animals were used as controls. The 
average life-span of these animals was 22.5 months. For the second experiment, 30 rats (15 males and 
15 females) were given the same diet with  10  000 mg of  Patent Blue V/kg diet, and also, a 
subcutaneous injection of 1 ml of 1 % Patent Blue V aqueous solution, once a week, for 15-19 months. 
The average life-span of the animals was 18 months. The last animal died at an age of 30 months. 
Twenty-six rats were used as controls and were given 1 ml of distilled water subcutaneously for the 
same period as the treated animals. The average life-span of these animals was 19 months. No 
abnormal histopathological findings or sarcomas at the site of injection were observed. 
3.2.5.  Reproductive and developmental toxicity 
Groups of 65 male and female mice were given diets containing 0.1, 0.3 or 1 % Patent Blue V 
(equivalent to 150, 500 and 1500 mg/kg bw/day) for 9 weeks prior to mating and throughout mating, Re-evaluation of Patent Blue V (E 131) as a food additive 
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gestation and rearing of their offspring (F1 generation) (IFREB, 1981, as referred to by BIBRA, 1982). 
No adverse effects were reported. No further details on the study were available to the Panel. The 
authors concluded that the NOAEL was 1500 mg/kg bw/day. 
In a developmental study, groups of 25 mated OFA (Sprague-Dawley derived) rats were fed diets 
containing 0, 0.3 or 1 % Patent Blue V (calcium salt), meeting JECFA specifications, equivalent to 0, 
150 and 500 mg/kg bw/day, from day 6 to 15 of gestation, and were killed 21 days after mating. No 
mortality was observed during the study and growth and food consumption was similar in all 3 groups. 
One female from the low-dose group with a single implantation miscarried during the study, and in 
one female from the high-dose group, total resorption occurred (12 implantations). The average 
number of resorptions, implantations and living foetuses and their weights did not appear to differ 
markedly between control and treatment groups (statistical comparisons were not reported). Skeletal 
staining of two-thirds of the offspring and organ examination and sectioning of the remaining 
offspring did not reveal any major or minor abnormality which might be related to treatment, but 
individual data were not reported (IFREB, 1978b, as referred to by BIBRA, 1982). 
The Panel agreed with the authors that the NOAEL of this study was 500 mg/kg bw/day, the highest 
dose tested. 
3.2.6.  Hypersensitivity, allergenicity, intolerance  
They are no reported cases of allergy or anaphylactic reactions after ingestion of Patent Blue V in 
humans. 
Allergic reactions to Patent Blue V have been reported from its use in surgery for the identification of 
the primary draining lymph nodes (sentinel nodes biopsy) in breast cancer and malignant melanoma. 
The incidence of reactions ranged from 0.6 % up to 2.7 %, and severe anaphylaxis is described in 0.06 
% of the cases (Scherer et al.,  2006; Barthelmes et al.,  2010; Bézu et al.,  2010). Most patients 
experiencing a severe allergic reaction had no particular medical history of allergy (Barthelmes et al., 
2010). 
An allergic reaction (erythematous urticarial rash) was also described after topical use of Patent Blue 
V in a healthy five year old girl with no history of atopic conditions, given a disclosing tablet 
containing Patent Blue V to demonstrate the presence of plaque on teeth (Chadwick et al., 1990).  
Anaphylactic reactions to Patent Blue V observed during surgery are likely to be mediated by IgE 
(Johansson et al., 2010) and are often characterized by an increased expression of CD63, a marker of 
activation in basophils (Eberlein-König et al., 2004; Johansson et al., 2010).  
Given its relatively low molecular weight and its capacity to (weakly) bind proteins, Patent Blue V 
may likely act as a hapten, with the carrier protein(s), sugar or lipid being so far unknown (Tsopelas et 
al., 2002; Johansson et al., 2010).  
The Panel noted that anaphylactic reactions to Patent Blue V occur during surgery. However, the 
application of Patent Blue V in various fields (cosmetics, textiles, paints, inks) could potentially cause 
sensitization to this colour. 
4.  Discussion 
The Panel was not provided with a newly submitted dossier and based its evaluation on previous 
evaluations, additional literature that became available since then and the data available following a 
public call for data. The Panel noted that not all original studies on which previous evaluations were 
based were available for re-evaluation by the Panel.  
Patent Blue V is a triarylmethane dye allowed as a food additive in the EU that has been previously 
evaluated by JECFA in 1970 and 1975, and the EU SCF in 1983. Re-evaluation of Patent Blue V (E 131) as a food additive 
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JECFA established a temporary ADI of 0-1 mg/kg bw/day in 1970, but withdrew it in 1975. Until now 
JECFA has not allocated an ADI to Patent Blue V. In 1983, the SCF established an ADI of 0-15 
mg/kg bw/day on the basis of a long-term toxicological study in mice, which had not been available 
for the JECFA evaluation in 1975. 
Furthermore, the Panel noted that the specifications on the purity of Patent Blue V would allow 
concentrations of unidentified unsulphonated aromatic amines to be present in concentrations of up to 
100 mg/kg Patent Blue V. Given the maximum allowed concentration of Patent Blue V that can be 
added to food (500 mg/kg food), the concentration of these amines in food could be up to 50 µg/kg 
food. Intake estimates of Patent Blue V at levels up to the ADI of 15 mg/kg bw/day could amount to 
intakes of these aromatic amines at levels up to 1.5 µg/kg bw/day. As some aromatic amines may be 
associated with genotoxicity or even carcinogenicity, this may give reason for concern. The Panel 
concluded that it would be prudent to modify the specifications to indicate that the level of 
unsulphonated aromatic amines should be as low as reasonably achievable. 
In vitro data on metabolism in humans and rats showed that Patent Blue V is not metabolised by rat or 
human hepatic microsomal enzymes. Data available on the absorption, distribution, metabolism and 
excretion of Patent Blue V after oral administration in rats and dogs show that Patent Blue V has low 
absorption, limited systemic availability and is mainly excreted unchanged in faeces. 
Concerning  subacute  and subchronic toxicity data,  only  one  subacute toxicity study  in dogs was 
available.  The effects reported in this study were  considered  by the Panel to be without any 
toxicological relevance, and the NOAEL was 280 mg/kg bw/day, the highest dose tested. 
Patent Blue V did not demonstrate any evidence of mutagenic activity in strains of tryptophan-
requiring Escherichia coli and histidine-requiring Salmonella typhimurium (4 strains), both with, and 
without metabolic activation in old studies. In contrast, Patent Blue V induced in the Ames test, 
performed (in 2010) according to OECD Guidelines, biologically significant increases in the number 
of revertants in the TA98 strain in the presence of metabolic activation at high concentrations of 
colour. In the presence of low concentrations, there were no effects. This observation could suggest 
that an impurity present in the food colour could be responsible for this mutagenic effect.  
A mouse lymphoma assay performed in 2011 according to OECD Guidelines with Patent Blue V in 
accordance with EU specifications, was negative.  
Two in vivo micronucleus assays are available for Patent Blue V. The first one (in 1986), performed in 
mouse after intraperitonal injection, was evaluated as not reliable..The second  one  (in 2011), 
performed in rat after intravenous injection did not show any clastogenic effect. 
In an unpublished  study report, the DNA damaging capabilities of Patent Blue V (E 131) were 
assessed in the in vivo single cell gel/Comet assay in rats. The Panel concluded that Patent Blue V (E 
131) does not induce any effect in DNA migration in rat liver, jejunum/ileum and peripheral blood 
after in vivo treatment under the reported experimental conditions.  
According to new studies provided by industry on request of EFSA, the Panel considered that Patent 
Blue V (E 131) (at purity level > than 90 %) is not of concern with respect to genotoxicity. 
There is one chronic toxicity study performed in mice. In the absence of the full study report, the Panel 
considered that the haematological effects observed at the highest dose tested are biologically 
significant. Therefore, the Panel considered that a NOAEL of 500 mg/kg bw/day (intermediate dose 
tested) can be derived from this study, based on growth reduction and alterations of haematological 
parameters reported at the highest dose tested mainly in males. Re-evaluation of Patent Blue V (E 131) as a food additive 
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A reproductive toxicity study in mice did not reveal adverse effects. The NOAEL is the highest dose 
tested, 1500 mg/kg bw/day. A developmental study in rats is available. No adverse effects have been 
identified. The NOAEL derived by the Panel was 500 mg/kg bw/day, the highest dose tested. 
The Panel concluded that the present dataset provided a rationale for a re-definition of the ADI. Using 
the NOAEL of 500 mg/kg bw/day from a chronic toxicity study in mice and applying an uncertainty 
factor of 100 to this NOAEL, the Panel established an ADI of 5 mg/kg bw/day for Patent Blue V of 
purity at least 90 %.  
Exposure to Patent Blue V from its use as a food additive has been calculated by using MPLs as 
indicated in the Commission Regulation No 1129/2011 and by using data on reported use levels 
provided by food industry or data reported on analytical levels provided by national authorities or 
found in the literature. These data were combined with national consumption data for the population 
groups of toddlers, children, adolescents, adults and the elderly from the EFSA Comprehensive Food 
Consumption Database. 
When considering MPLs, estimates calculated for toddlers, children, adolescents, adults and the 
elderly give dietary exposures at the mean in the range of 1-4.5, 1.1-3.6, 0.5-1.8, 0.3-1.4, and 0.2-0.6 
mg/kg bw/day, respectively. High level exposures for these population groups were calculated to be in 
the range of 2.9-7.5, 2.4-7, 1.3-3.7, 0.9-2.9 and 0.6-1.5  mg/kg bw/day, respectively. The main 
contributors to the total anticipated exposure to Patent Blue V (>10 %) for adults were flavoured 
drinks (with sugar or with sweeteners) (11-48 %), flavoured fermented milk products (14-29 %), fine 
bakery wares (11-34  %), and sauces (12-29  %). For children, main contributors were flavoured 
fermented milk products (13-32 %), fine bakery wares (11-45 %), and sauces (11-23 %).  
When considering maximum reported use levels or maximum analytical levels, estimates calculated 
for toddlers, children, adolescents, adults and the elderly give dietary exposures at the mean in the 
range  of 0.2-1.5, 0.4-1.2, 0.3-0.7, 0.1-0.5 and 0.04-0.3  mg/kg bw/day, respectively. High level 
exposures for these population groups were calculated to be in the range of 0.6-2.7, 1-2.4, 0.7-1.7, 0.4-
1 and 0.1-0.8 mg/kg bw/day, respectively. The main contributors to the total anticipated exposure to 
Patent Blue V (>10 %) for adults were flavoured drinks with sweeteners (12-38 %), and fine bakery 
wares (15-64 %). For children, main contributors were fine bakery wares (10-70 %), and flavoured 
drinks with sugar (10-31 %).  
The Panel noted that at the maximum permitted levels of use of Patent Blue V, exposure estimates for 
high consumers are above the ADI of 5 mg/kg bw/day in toddlers and children population. At the 
maximum reported use levels of Patent Blue V, exposure estimates are below the ADI of 5 mg/kg 
bw/day for all groups of the population. 
The Panel further noted that the specifications of Patent Blue V need to be updated with respect to the 
percentage of material not accounted for that may represent sodium chloride and/or sodium sulphate as 
the principal uncoloured components. 
The Panel noted that the JECFA specification for chromium is < 50 mg/kg, whereas no specification 
for chromium is required in EC specifications. 
The Panel noted that the aluminium lake of the colour could add to the daily intake of aluminium for 
which a TWI of 1 mg aluminium/kg bw/week has been established and that therefore specifications 
for the maximum level of aluminium in the lakes may be required. 
CONCLUSIONS  
Patent Blue V (E 131) is a triarylmethane dye permitted for use as a food additive in the EU, that has 
been previously evaluated by JECFA in 1970 and 1975 and the EU SCF in 1983. JECFA established a Re-evaluation of Patent Blue V (E 131) as a food additive 
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temporary ADI of 0-1 mg/kg bw/day in 1970 but withdrew it in 1975. In 1983, the SCF established an 
ADI of 0-15 mg/kg bw/day. 
The Panel concluded that the present dataset provided a rationale for re-definition of the ADI. Using 
the NOAEL of 500 mg/kg bw/day from a chronic toxicity study in mice and applying an uncertainty 
factor of 100 to this NOAEL, the Panel established an ADI of 5 mg/kg bw/day for Patent Blue V. The 
Panel considered that this ADI will only apply to Patent Blue V with a purity of at least 90 %. 
The Panel noted that at the maximum permitted levels of use of Patent Blue V, exposure estimates for 
high consumers are above the ADI of 5 mg/kg bw/day in toddlers and children. At the maximum 
reported use levels of Patent Blue V, exposure estimates are below the ADI of 5 mg/kg bw/day for all 
groups of the population. 
The Panel further noted that the specifications for Patent Blue V need to be updated with respect to the 
percentage of material not accounted for that may represent sodium chloride and/or sodium sulphate as 
the principal uncoloured components.  
The Panel noted that the JECFA specification for chromium is < 50 mg/kg, whereas no specification 
for chromium is required in EC specifications. 
The Panel noted that the aluminium lake of the colour could add to the daily intake of aluminium and 
that therefore specifications for the maximum level of aluminium in the lakes are required. 
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D 53007, May 22, 2009). 
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for the Union of European Beverages Associations (UNESDA), December 2006. 
4.  Guerbet/Eurofins, 2011. Study of Patent Blue V metabolisation on human and rat microsome. 
Unpublished Report. 88 pages. February 16, 2011. Submitted to EFSA on March 25, 2011. 
5.  Guerbet/Ricerca, 2011a. Patent Blue V – In vitro Mammalian Cell Gene Mutation Patent Blue V – 
In vitro  Mammalian Cell Gene Mutation Test on L5178Y Mouse Lymphoma Cells TK
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2011. 
7.  Guerbet/Ricerca, 2010. Patent Blue V - Bacterial reverse mutation test (Plate incorporation and 
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on April 5, 2011. 
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10. Fiorio Colori, 2012b. Patent Blue V (E 131). Authorisation of an existing feed additive product in 
the European Union already authorised as food additive. Section II, Identity, Characterisation and 
Conditions of Use of the Additive; Method of Analysis (volume 2). Submitted to EFSA on 15 
June, 2012. 
11. IFREB, 1978a. Essai toxicologique de 3 mois par incorporation dans le régime chez le chien 
Beagle. Institut Français de Recherches et Essais Biologiques Colourant E 131 (Bleu Patent V). 
IFREB Report N° 806216, 1978 (unpublished report). 
12. LEMM, 1978c. Séparation des métabolites radioactifs du Bleu Patent-
14C (E 131). Fascicule II. 
Laboratoire d’Etudes du métabolisme des Médicaments 1978 (unpublished report). 
13. Slovakia, Ministry of Agriculture and Rural Development, Food Safety and Nutrition Department. 
Analytical data on Patent Blue (E 131), 2009-2010. Submitted to EFSA on 3 May, 2011. 
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ANNEX A 
RULES DEFINED BY THE PANEL TO DEAL WITH QUANTUM SATIS (QS) AUTHORISATION, 
USAGE DATA OR OBSERVED ANALYTICAL DATA FOR ALL REGULATED FOOD ADDITIVES TO BE 
RE-EVALUATED  
 
Figure 1:  Rules defined by the Panel to deal with usage data or observed analytical data for all 
regulated food additives to be re-evaluated and procedures for estimating intakes using 
these rules. 
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Figure 2:  Rules defined by the Panel to deal with quantum satis (QS) authorisation. 
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GLOSSARY/ABBREVIATIONS 
ADI  Acceptable Daily Intake 
Aluminium lakes   Aluminium lakes are produced by the absorption of water soluble dyes ont        
substrate rendering the colour insoluble in water. The end product is coloured         
the lake into the product or by coating onto the surface of the product 
ANS  Panel on Food Additives and Nutrient Sources added to Food 
bw  Body weight 
CAS  Chemical Abstract Service 
CIAA  Confederation of the Food and Drink Industries of the EU 
EC  European Commission 
EFSA  European Food Safety Authority 
EMS  Ethyl methanesulphonate 
EU  European Union 
FSA  UK Food Standards Agency,  
FAO/WHO   Food and Agriculture Organization/World Health Organization 
FSAI  Food Safety Authority of Ireland  
FpG  Fapy-DNA glycosylase 
GLP  Good Laboratory Practice 
HPLC  High-Performance Liquid Chromatography 
IARC  The International Agency for Research on Cancer 
JECFA  Joint FAO/WHO/Expert Committee on Food Additives 
LD50  Lethal Dose, 50 % i.e. dose that causes death among 50 % of treated animals 
LOD  Limit if Detection  
LOQ  Limit of Quantification  
MNPCEs  Micronucleated Polychromatic erythrocytes 
MPL  Maximum Permitted Level 
NATCOL  Natural Food Colours Association 
NDNS  UK National Diet and Nutrition Survey 
NOAEL  No-Observed-Adverse-Effect Level 
NCEs  Normochromatic Erythrocytes 
OECD  Organisation for Economic Co-operation and Development 
PCEs  Polychromatic Erythrocytes 
QS  Quantum Satis 
SCF  Scientific Committee for Food 
SCOOP   A scientific cooperation (SCOOP) task involves coordination amongst Me        
pooled data from across the EU on particular issues of concern regarding food   
TWI  Tolerable Weekly Intake Re-evaluation of Patent Blue V (E 131) as a food additive 
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UNESDA  Union of European Beverage Associations  
UV/VIS   Ultra-Violet/Visible Spectrum 
 